Table 1

Baseline characteristics of study trials and participants

Index conditionNo (%) of trialsMean (SD) age (years)Sex (No (%))Trial attrition
(proportion)
Mean (SD) comorbidity count>2 comorbidities (proportion)
Atrial fibrillation171.7 (8.4)Female (6554 (36.3))0.111.1 (0.0)0.29
Male (11 479 (63.7))0.11
Axial spondyloarthritis241.4 (11.7)Female (91 (28.4))0.050.9 (0.1)0.22
Male (229 (71.6))0.02
Benign prostatic hyperplasia663.4 (8.5)Female1.2 (0.7)0.37
Male (2816 (100.0))0.06
Chronic idiopathic urticaria342.6 (14.1)Female (719 (73.5))0.141.6 (0.6)0.48
Male (259 (26.5))0.14
Dementia (any)374.2 (7.8)Female (1473 (59.6))0.301.8 (0.4)0.56
Male (999 (40.4))0.26
Type 2 diabetes mellitus1857.3 (9.3)Female (8091 (43.4))0.241.1 (0.5)0.29
Male (10 559 (56.6))0.23
Hypertension954.5 (15.6)Female (2202 (42.7))0.120.6 (0.3)0.12
Male (2949 (57.3))0.12
Pulmonary hypertension154.5 (15.6)Female (318 (78.3))0.132.1 (0)0.58
Male (88 (21.7))0.13
Inflammatory bowel disease1038.5 (12.6)Female (2272 (49.3))0.190.8 (0.2)0.20
Male (2336 (50.7))0.20
Knee arthroplasty166.1 (9.5)Female (1494 (57.6))0.072.5 (0)0.65
Male (1099 (42.4))0.07
Migraine539.1 (12.3)Female (1250 (85.4))0.251 (0.6)0.21
Male (214 (14.6))0.27
Osteoarthritis163.7 (11.7)Female (888 (67.3))0.111.8 (0)0.54
Male (432 (32.7))0.11
Osteoporosis156.5 (13.9)Female (345 (80.4))0.442.7 (0)0.84
Male (84 (19.6))0.44
Parkinson’s disease (all)361.7 (10)Female
577 (42.2)
0.121.4 (0.6)0.41
Male (791 (57.8))0.12
Psoriasis445 (12.8)Female (836 (30.8))0.010.3 (0.2)0.70
Male (1878 (39.2))0.01
Psoriatic arthropathy347.5 (11.5)Female (266 (44.4))0.140.5 (0.4)0.14
Male (333 (55.6))0.10
Pulmonary fibrosis266.9 (8.1)Female (220 (20.7))0.170.4 (0.1)0.09
Male (843 (79.3))0.17
Restless legs syndrome253.9 (12.7)Female (414 (61.2))0.241.6 (0.2)0.50
Male (262 (38.8))0.24
Rheumatoid arthritis1052.3 (12)Female (4507 (80.2))0.211.3 (0.4)0.34
Male (1111 (19.8))0.21
Thromboembolism757.8 (13.7)Female (8106 (44.8))0.131.1 (0.5)0.32
Male (9985 (55.2))0.13
  • SD=standard deviation.